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Abstract
Background—Genome-wide association studies have identified at least 15 independent
common genetic variants associated with colorectal cancer (CRC) risk. The aim of this study was
to investigate whether 11 of these variants are associated with CRC risk for carriers of germline
mutations in DNA mismatch repair (MMR) genes.
Methods—A total of 927 MMR gene mutation carriers (360 MLH1, 442 MSH2, 85 MSH6 and
40 PMS2) from 315 families enrolled in the Colon Cancer Family Registry, were genotyped for
the SNPs: rs16892766 (8q23.3), rs6983267 (8q24.21), rs719725 (9p24), rs10795668 (10p14),
rs3802842 (11q23.1), rs4444235 (14q22.2), rs4779584 (15q13.3), rs9929218 (16q22.1),
rs4939827 (18q21.1), rs10411210 (19q13.1) and rs961253 (20p12.3). We used a weighted Cox
regression to estimate CRC risk for homozygous and heterozygous carriers of the risk allele
compared with homozygous non-carriers as well as for an additive per allele model (on the log
scale).
Results—Over a total of 40,978 person-years observation, 426 (46%) carriers were diagnosed
with CRC at a mean age of 44.3 years. For all carriers combined, we found no evidence of an
association between CRC risk and the total number of risk alleles (hazard ratio [HR] per risk
allele=0.97, 95% confidence interval [CI]=0.88–1.07, p=0.52).
Conclusions—We found no evidence that the SNPs associated with CRC in the general
population are modifiers of the risk for MMR gene mutation carriers overall, and therefore any
evidence of proven clinical utility in Lynch syndrome.
Keywords
genetic variant; colorectal cancer; Lynch syndrome; mismatch repair
INTRODUCTION
Colorectal cancer (CRC) is one of the most frequently diagnosed cancers worldwide, with
over one million diagnosed cases (9.8% of cancer diagnoses) and ~600,000 deaths (8.1% of
all cancer deaths) in 2008(1). Approximately 3–4% of all CRC(2), and 5–15% of CRC
diagnosed before age 50 years(3, 4), are Lynch syndrome cases caused by germline
mutations in a DNA mismatch repair (MMR) gene; MLH1, MSH2, MSH6 and PMS2(5).
Average cumulative risk of CRC to age 70 years for MMR gene mutation carriers has been
varyingly estimated between 20% and 70% depending on sex and the MMR gene that is
mutated(6–8). Cancer risks for MLH1 and MSH2 mutation carriers vary greatly from family
to family(9), consistent with the existence of multiple inherited genetic (polygenic)
modifiers.
Several genome-wide association studies (GWAS) have identified single nucleotide
polymorphisms (SNPs) in at least 15 independent loci associated with CRC risk (odds ratio
ranging from 1.10 to 1.26 per risk allele)(10–12) (Supplementary Table 1). If these SNPs
also predicted CRC risk in MMR gene mutation carriers, there would be a potential to use
them to more accurately predict individual risk estimates for Lynch syndrome. Three studies
observed two variants, 8q23.3 (rs16892766) and 11q23.1 (rs3802842), to be associated with
increased risk of CRC in Lynch syndrome especially for females only(13, 14) or MLH1
mutation carriers only(14, 15); however, another study(16) observe no associations. In this
study of MMR gene mutation carriers, we have investigated associations of CRC with SNPs
at 11 loci: 8q23.3 (rs16892766), 8q24.21 (rs6983267), 9p24 (rs719725), 10p14
(rs10795668), 11q23.1 (rs3802842), 14q22.2 (rs4444235), 15q13.3 (rs4779584), 16q22.1
(rs9929218), 18q21.1 (rs4939827), 19q13.1 (rs10411210) and 20p12.3 (rs961253).
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MATERIALS AND METHODS
Study Sample
Subjects were heterozygote carriers of pathogenic mutations in MMR genes who were
recruited from the Colon Cancer Family Registry (Colon CFR). Details of recruitment, data
collection and mutation testing have been described in detail previously(17, 18). Written
informed consent was obtained from all subjects, and the study protocol was approved by
the institutional human ethics committee at each center of the Colon CFR.
Genotyping of the SNPs
Genotyping for SNPs was performed using Sequenom’s iPLEX Gold. PCR and extension
primers for these SNPs were designed using the MassARRAY Assay Design 3.0 software
(Sequenom, Inc.). Extension product sizes were determined by mass spectrometry using
Sequenom’s Compact matrix-assisted laser desorption ionization-time of flight mass
spectrometer. Resulting mass spectra were converted to genotype data using
SpectroTYPER-RT software. Genotype data from 30 CEPH trios (Coriell Cell Repository,
Camden, NJ) were used to confirm reliability and reproducibility of the genotyping. No
errors of Mendelian inheritance were detected in the CEPH trios and genotypes for these
subjects showed perfect concordance with genotypes from the International HapMap
Project.
Statistical Analysis
Cox proportional hazards regression analysis was used to estimate hazard ratios (HRs) and
95% confidence intervals (CIs) for the published CRC risk allele of each SNP to CRC risk
for MMR gene mutation carriers. We estimated HRs separately for homozygous carriers of
the risk allele (2 risk alleles) and heterozygous carriers of the risk allele (1 risk allele) versus
homozygous carriers of the non-risk allele (0 risk allele); and we estimated HRs per risk
allele, i.e. a linear association on the log scale. We also estimated the association with the
total number of risk alleles over the SNPs, i.e. 0–22. (see Supplementary Table 1 for risk
alleles).
Since some carriers were ascertained because they were diagnosed with CRC, the
identification of MMR gene mutation carriers was not random with respect to CRC. To
adjust for this non-random ascertainment, we used the weighted cohort approach(19).
Previously estimated age-specific CRC incidence rates for MMR gene mutation carriers(20)
were used to calculate sampling fractions to weight the proportion of CRC-affected and
unaffected carriers in 5-year age stratum so the proportion of affected carriers in each age
group equalled that expected for mutation carriers in the population.
Time-at-risk started at birth and ended at age at diagnosis of CRC (n = 426), any other
cancer (n = 92), polypectomy (n = 132), death (n = 4) or last contact (n = 273), whichever
occurred first. Proportional hazards assumption was tested by examining the relationship
between the scaled Schoenfeld residuals and survival time (21). Associations between
genetic variants and CRC risk were estimated stratified by gender and the MMR gene that
was mutated after adjusting for country of recruitment and ascertainment source (clinic- or
population-based). To allow for any correlation of risk between family members, the Huber-
White robust variance correction was applied by clustering on family membership (22).
To reduce false discovery rate expected from the large number of associations investigated,
the p-value cut-off for classifying a HR as statistically significant was determined using
methods by Benjamini and Hochberg (23). This method controls the expected high false
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discovery rate and can result in power gains over traditional multiplicity ‘correction’
methods such as the Bonferroni procedure(24).
A test of the null hypothesis (no association between any of the genetic variants and CRC
risk) against the alternative hypothesis (associations with CRC risk in the same direction as
in the general population) was conducted using Fisher’s test of whether the distribution of
one-sided p-values from fitting the additive per allele association on the log scale deviated
from the uniform distribution on the interval [0, 1]. This was done by summing the −2 ln pi,
where pi is the p-value for the ith variant, across all SNPs and comparing with the
χ2 distribution with 2n degrees of freedom, where n is the number of SNPs(25). Statistical
analyses were performed using Stata 11.0(26).
RESULTS
A total of 927 MMR gene mutation carriers from 315 families (117 MLH1, 136 MSH2, 41
MSH6, and 21 PMS2) were included in this study. Over 40,978 person-years observation,
426 (46%) carriers were diagnosed with CRC at a mean age of 44.3 (standard deviation, SD
11; median 44, range 17–80) years. Of all carriers, 738 (223 families) were recruited in
Australia or New Zealand, 164 (77 families) in the USA and 25 (15 families) in Canada
(Table 1). SNP genotype frequencies did not deviate from that expected under Hardy–
Weinberg equilibrium except for rs3802842 (p=0.004) and rs6983267 (p=0.002) (Table 2).
We found no evidence of an increased CRC risk associated with any of the 11 SNPs overall
or separately for male and female carriers (Figure 1 and 2). Also, there was no evidence of
an association between the total number of risk alleles of the 11 SNPs (as a continuous
factor) and CRC risk (HR per risk allele=0.97, 95%CI=0.88–1.07, p=0.52 all carriers
combined; HR=0.99, 95%CI=0.86–1.14,p=0.87 for males; HR=0.96, 95%CI=0.84–1.10,
p=0.56 for females; HR=0.98, 95%CI=0.82–1.18, p=0.86 for MLH1; HR=0.95,
95%CI=0.82–1.10, p=0.50 for MSH2, HR=1.03, 95%CI=0.85–1.26,p=0.74 for MSH6;
HR=0.82, 95%CI=0.50–1.32, p=0.41 for PMS2). We also found no evidence of variation
from a uniform distribution of CRC risk for the SNPs (p=0.53 for all carriers combined, 0.83
for males, 0.72 for females, 0.80 for MLH1, 0.61 for MSH2, 0.0005 for MSH6 and 0.39 for
PMS2).
For PMS2 mutation carriers, carriers of the G-allele of rs10795668 (10p14) were at
decreased risk of CRC (HR=0.07, 95%CI=0.01–0.40, p=0.003 for AG carriers; and
HR=0.03, 95%CI=0.00–0.39, p=0.007 for GG carriers compared with AA carriers). For
PMS2 mutation carriers, carriers of the G-allele of rs992918 (16q22.1) were also at
decreased risk of CRC (HR=0.14, 95%CI=0.03–0.61, p=0.009 for GA carriers; and
HR=0.07, 95%CI=0.01–0.51, p=0.008 for GG carriers compared with AA carriers). For
MSH2 mutation carriers, homozygous carriers of the C allele of rs16892766 were at
increased risk of CRC compared with homozygous carriers of the A allele (HR=10.74,
95%CI=2.24–51.39, p=0.003) (Table 3).
DISCUSSION
Our analyses provided no evidence to support the hypothesis that, overall, the SNPs
associated with CRC risk for the general population are also associated with CRC risk for
MMR gene mutation carriers, let alone having associations in the same direction. We found
no evidence for SNP associations with CRC for all carriers combined, or when stratified by
gender. Our estimate of CRC risk per allele for mutation carriers (HR=0.97, 95%CI=0.88–
1.07) was lower (p=0.03) than reported for the general population (OR=1.09, 95%CI=1.05–
1.13) (27).
Win et al. Page 4
Eur J Cancer. Author manuscript; available in PMC 2014 May 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
These findings strongly suggest that the GWAS SNPs for CRC in the general population are
not useful predictors for CRC in those with an inherited MMR gene mutation. Whatever the
reason for the association between these SNPs and CRC, whether it be due to linkage
disequilibrium with a common or rare causal genetic variant, protein binding site or
promoter region, they do not appear to be having the same effect in carriers of high-risk
mutations. Perhaps cancers with microsatellite instability, i.e. Lynch syndrome cancers, are
not subject to the same slight effects that these SNPs have on the more common
microsatellite stable cancers. Is this apparent lack of SNP and cancer association carriers of
MMR gene mutations also seen for carriers of other high-risk cancer genes? Two of the six
GWAS SNPs associated with breast cancer in the general population were also associated
with breast cancer risk for carriers of BRCA1 mutations, and five of the six SNPs were
associated with breast cancer risk for BRCA2 mutation carriers(28). It appears then, that the
predictive utility of SNPs identified by GWAS using cancer in the general population, for
predicting cancer in carriers of high-risk mutations, may depend on the specific high-risk
gene; no utility for MMR genes; almost no utility for BRCA1, and some utility for BRCA2.
Further, as shown in Figure 1, for all carriers combined, only 3 of SNPs had a point estimate
greater than one for the OR per allele for association with CRC. If these associations for
MMR gene mutation carriers were consistent with studies for the general population, we
would expect all of the SNPs to be positively associated with risk, i.e. OR>1. The apparent
difference in estimates for SNP associations with CRC between MMR gene mutation
carriers and the general population might be due to differences in the pathogenesis of these
cancers, as exemplified by differences in tumor location in the large intestine. Proximal and
distal colon have been different gene expression profiles and risk factors(29–31). Lynch
syndrome-associated CRCs are more likely to present in the proximal colon compared with
CRCs in the general population. In addition, differential effects for SNPs may also arise due
to the differing mechanisms of carcinogenesis: Lynch syndrome, specifically progression via
microsatellite instability, in contrast with the chromosomal instability which characterises
population-based CRC.
This is the only study assessing the CRC SNPs for PMS2 mutation carriers. We observed
heterozygous and homozygous carriers of the G alleles for the rs10795668 and rs9929218
SNPs were at decreased CRC risk, i.e. the opposite direction to that observed for the general
population. Although our study group consisted of only 40 PMS2 mutation carriers, the
observed associations were significant after correction for multiple testing––suggesting
these findings are not spurious. However, further validation in larger sample set of PMS2
mutation carriers is necessary. There was evidence suggesting that rs10795668 varied by
tumor site, being more common in rectal than colonic tumors(32). In contrast, Lynch
syndrome associated CRCs occur predominantly in the proximal colon and therefore, the
findings from this study for rs10795668 in PMS2 mutation carriers may reflect an indirect
association related to tumor location.
The association between homozygous carriers of the C allele of rs16892766 and CRC risk
for MSH2 mutation carriers was in the same direction as reported for CRC from the general
population(32). In the general population, the association was stronger for CRC diagnosed
under age 60 years suggesting potential age modifying effects in MMR gene mutation
carriers. This SNP has also been reported as a CRC risk modifier for MMR gene mutation
carriers in three other studies(13–15); but not in one study(16). Talseth-Palmer et al.(14) did
not observe a significant effect of rs16892766 alone on CRC risk but observed a trend of an
increased risk of CRC for the pair-wise combination of SNPs rs3802842 and rs16892766 in
MLH1 mutation carriers. In contrast, Houlle et al.(16) reported a decreased risk of CRC
(HR=0.27, 95%CI=0.08–0.86, p=0.03) for homozygous carriers of the C allele in mutation
carriers overall. The lack of consistency in the results between our study and this study(16)
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could be attributable to the small number of homozygous carriers of the C allele of
rs16892766 identified in each study. We concluded a meta-analysis of combining data from
our study with the four previous studies(13–16), as infeasible given our study and another
one study(13) used a weighted approach(19) while others did not(14–16).
A limitation of our study was the possibility that the estimates of association were only
generalizable to MMR gene mutation carriers with substantial survival as, to be included in
the analysis, cases had to survive long enough to provide a blood sample for DNA testing.
Another limitation is that we had limited data on the type of colorectal polyps, which were
removed, and therefore we censored at the age of polypectomy instead of estimating post-
polypectomy CRC risk. This could have resulted in underestimating the true cancer risk if
some of the polyps were malignant. Finally, the study was underpowered to detect weak
associations of the SNPs with CRC risk. Assuming the risk allele frequency of each SNP to
be 45% in unaffected carriers, our study of 927 MMR gene mutation carriers had 68%
power to detect a 20% increased or decreased risk of CRC, and 23% power to detect a 10%
increased or decreased risk of CRC, at the 0.05 level of significance.
Future studies should include a further four SNPs not included in this analysis that have
been confirmed as being associated with CRC (1q41, 3q26.2, 12q13.13 and 20q13.33)(12).
In addition, our study chose SNPs a priori based on previous associations with CRC in
GWAS from the general population. It is unclear whether any of the millions of other SNPs
tested, but not previously associated with CRC in the general population, may predict CRC
risk for MMR gene mutation carriers.
In conclusion, our findings suggest that 11 SNPs identified from previous GWAS that were
known to be associated with CRC risk in those general populations studied do not
substantially alter the CRC risk of MMR gene mutation carriers. Therefore we found no
evidence of proven clinical utility for these SNPs for Lynch syndrome carriers. The search
for the hypothesized genetic modifiers of cancer risk due to MMR mutations should
therefore examine other SNPs. Genome-wide association studies of Lynch syndrome
colorectal cancer cases and controls is needed to identify these SNP modifiers, but given the
rarity of the syndrome, international collaborations would be required to gain sufficient
statistical power to adequately address this question.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.
Hazard ratios and 95% confidence intervals for associations between common genetic
variants and colorectal cancer risk for mismatch repair gene mutation carriers.
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Figure 2.
Hazard ratios and 95% confidence intervals for associations between common genetic
variants and colorectal cancer risk for carriers of mutations in specific mismatch repair gene.
Note: Horizontal lines represent 95% confidence intervals. Each dot represents the point
estimate for hazard ratio per allele. X-axis as log scale.
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Table 1
Baseline characteristics of mismatch repair gene mutation carriers included in the study
No colorectal cancer
(n=501)
N (%)
Colorectal cancer
(n=426)
N (%)
All
(n=927)
N (%)
Sex
male 204 (41) 204 (48) 408 (44)
female 297 (59) 222 (52) 519 (56)
Country
Canada 6 (1) 19 (4) 25 (3)
Australia or New Zealand 429 (86) 309 (73) 738 (80)
USA 66 (13) 98 (23) 164 (17)
Ascertainment
Population-based 56 (11) 87 (20) 143 (15)
Clinic-based 445 (89) 339 (80) 784 (85)
Gene mutated
MLH1 180 (36) 180 (42) 360 (39)
MSH2 252 (50) 190 (45) 442 (87)
MSH6 53 (11) 32 (8) 85 (9)
PMS2 16 (3) 24 (5) 40 (4)
  Age* Mean (SD) 44.15 (14.17) 44.26 (11.05) 44.20 (12.82)
*Age at diagnosis for carriers with colorectal cancer; age at diagnosis of other cancer or polypectomy or death or last contact for carriers without
colorectal cancer.
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Table 2
Minor allele frequency of 11 SNPs included in the study
No colorectal
cancer
Colorectal
cancer All
rs10411210 [T] 0.12 0.13 0.12
rs10795668 [A] 0.30 0.30 0.30
rs16892766 [C] 0.06 0.08 0.07
rs3802842 [C] 0.28 0.29 0.29
rs4444235 [C] 0.47 0.48 0.48
rs4779584 [T] 0.23 0.22 0.22
rs4939827 [T] 0.46 0.48 0.49
rs6983267 [T] 0.45 0.48 0.47
rs719725 [C] 0.36 0.34 0.35
rs961253 [A] 0.38 0.36 0.37
rs9929218 [A] 0.29 0.30 0.29
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